NCT02133846 - Safety Study of TPI-287 to Treat CBS and PSP | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions

Primary Four Repeat Tauopathies (4RT)Corticobasal Syndrome (CBS)Progressive Supranuclear Palsy (PSP)Corticobasal Degeneration (CBD)

Interventions

DRUG

TPI 287 2 mg/m2

2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.

DRUG

TPI-287 20 mg/m2

20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class

DRUG

Placebo

500mL 0.9% sodium chloride

DRUG

TPI-287 6.3 mg/m2

6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class

Trial Locations (2)

35294

University of Alabama, Birmingham

94158

University of California, San Francisco, San Francisco